BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, Burriss SW, Gairy K, Maurik AV, Roth DA. 10 Years of belimumab experience: What have we learnt? Lupus 2021;:9612033211028653. [PMID: 34238087 DOI: 10.1177/09612033211028653] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Cui JY, Zhang L. Clinical efficacy and safety of sirolimus in childhood-onset systemic lupus erythematosus in real world. Medicine (Baltimore) 2022;101:e31551. [PMID: 36401486 DOI: 10.1097/MD.0000000000031551] [Reference Citation Analysis]
2 Krustev E, Clarke AE, Barber MR. B cell depletion and inhibition in systemic lupus erythematosus. Expert Review of Clinical Immunology 2022. [DOI: 10.1080/1744666x.2023.2145281] [Reference Citation Analysis]
3 Hunnicutt JN, Fairburn-beech J, Georgiou ME, Richards A, Gregan YI, Quasny H, Chauhan D. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study. Lupus Sci Med 2022;9:e000710. [DOI: 10.1136/lupus-2022-000710] [Reference Citation Analysis]
4 Rojas-rivera JE, García-carro C, Ávila AI, Espino M, Espinosa M, Fernández-juárez G, Fulladosa X, Goicoechea M, Macía M, Morales E, Quintana Porras LF, Praga M. Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. Nefrología 2022. [DOI: 10.1016/j.nefro.2022.10.005] [Reference Citation Analysis]
5 Zhang L, Cui J, Zhang L. Clinical efficacy and safety of sirolimus in childhood-onset systemic lupus erythematosus in real world.. [DOI: 10.21203/rs.3.rs-1993137/v1] [Reference Citation Analysis]
6 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun 2022;:102873. [PMID: 35963808 DOI: 10.1016/j.jaut.2022.102873] [Reference Citation Analysis]
8 Nakai T, Fukui S, Kidoguchi G, Ikeda Y, Kitada A, Nomura A, Tamaki H, Kishimoto M, Okada M. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus. Clin Rheumatol 2022. [PMID: 35939162 DOI: 10.1007/s10067-022-06325-6] [Reference Citation Analysis]
9 Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, Xu K. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol 2022;13:940416. [DOI: 10.3389/fimmu.2022.940416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Uresti-Rivera EE, García-Hernández MH. AIM2-inflammasome role in systemic lupus erythematous and rheumatoid arthritis. Autoimmunity 2022;:1-12. [PMID: 35880661 DOI: 10.1080/08916934.2022.2103802] [Reference Citation Analysis]
11 Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2022. [PMID: 35546484 DOI: 10.2217/cer-2022-0040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Patil S, Mustaq S, Hosmani J, Khan ZA, Yadalam PK, Ahmed ZH, Bhandi S, Awan KH. Advancement in therapeutic strategies for immune-mediated oral diseases. Dis Mon 2022;:101352. [PMID: 35339251 DOI: 10.1016/j.disamonth.2022.101352] [Reference Citation Analysis]
13 Salvadori M, Tsalouchos A. Innovative immunosuppression in kidney transplantation: A challenge for unmet needs. World J Transplant 2022; 12(3): 27-41 [DOI: 10.5500/wjt.v12.i3.27] [Reference Citation Analysis]
14 Sim TM, Ong SJ, Mak A, Tay SH. Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside. Int J Mol Sci 2022;23:2505. [PMID: 35269647 DOI: 10.3390/ijms23052505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Deng WP. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children. Zhongguo Dang Dai Er Ke Za Zhi 2021;23:1069-74. [PMID: 34719425 DOI: 10.7499/j.issn.1008-8830.2107153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Naučno-praktičeskaâ revmatologiâ 2021;59:367-383. [DOI: 10.47360/1995-4484-2021-367-383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Abraham R, Durkee M, Ai J, Veselits M, Casella G, Asano Y, Chang A, Ko K, Oshinsky C, Peninger E, Giger M, Clark MR. In lupus nephritis, specific in situ inflammatory states are associated with refractory disease and progression to renal failure.. [DOI: 10.1101/2021.09.03.458909] [Reference Citation Analysis]